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thymoma types B2, B3, and, of course, thymic carcinoma. In the case 
of thymoma (B2, B3), there is good retrospective evidence that local 
irradiation deﬁnitely reduces the rate of recurrences by 20%. 
In conclusion, WHO type A, AB, and B1 thymoma types do not need 
adjuvant treatment, if surgical resection is complete. WHO type B2 and 
B3, as well as combined tumours and thymic carcinoma proﬁt from ad-
juvant treatment which should at least be directed to local recurrences 
(local irradiation) or imply adjuvant chemotherapy (1,10). No prospec-
tive clinical studies are available. 
Pathogenesis of thymoma-associated autoimmune phenomena
Thymomas are associated to a large variety of autoimmune phenomena 
where myasthenia gravis is the most frequent and classical paraneo-
plastic autoimmune disease. A detailed functional analysis of thymoma 
associated with myasthenia gravis reveals that these tumours produce 
and export autoreactive CD4+ T cells into the periphery (while thymo-
mas not associated to myasthenia gravis do not). A major effect related 
to the generation of autoimmune disease may be attributed to the 
ﬁnding that within these tumours the production of adequate numbers 
of regulatory T cells (CD4+, CD25+) is signiﬁcantly decreased (10,11). 
Further pathogenetic ﬁndings related to thymomas associated myas-
thenia gravis shows that polymorphisms in the co-stimulatory recep-
tor CTLR4 with high expression is found in patients with thymoma 
( 2). Furthermore, the already cited hemizygous expression of MHC 
molecules is deﬁnitely a factors increasing the overall probability of au-
toimmune diseases in these patients. The ﬁndings imply that tumour-as-
sociated intratumourous defects of T cell differentiation are the reason 
for these autoimmune diseases and that different pathogenetic pathways 
may play a role. 
Differential diagnosis of thymic carcinoma
Mediastinal involvement by carcinoma may be derived from different 
primary sites. The differential diagnosis of squamous cell carcinoma 
of thymus vs. lung is the most challenging problem. Some topographic 
and structural features favour a thymic origin:
If the squamous cell carcinoma is adjacent to thymoma or combined 
with thymoma type B3, a thymic origin is very likely. Prominent 
perivascular spaces in the tumour and the overall lobular architecture 
also suggests thymic squamous cell carcinoma (TSCC). Furthermore, 
immunohistochemical ﬁndings may help: thymic squamous cell 
carcinomas often express CD5 and CD70, and may contain myoid 
cells (similar to the normal thymus). The value and sensitivity of CD5 
expression in the most frequent subtype (SCC) is about 60%, but the 
speciﬁcity in squamous cell carcinoma is almost absolute. Another 
highly sensitive and speciﬁc marker is the expression of the c-kit 
tyrosin kinase receptor (CD117). Expression is found In squamous 
cell carcinoma of the thymus in 90% whereas it is seen in pulmonary 
squamous cell carcinoma only in 5% (8). Further differences reside on 
genetic characterization. A typical loss of the long arm of chromosome 
16 (16q-) or the combination of 16q- with deletions on chromosome 6 
or ampliﬁcation of chromosome 18 are highly predictive for a primary 
thymic tumour in comparison to lung or squamous cell carcinoma of 
the upper respiratory track. 
Conclusion
The diagnosis of thymoma and thymic carcinoma is now in a stage 
where an agreed histopathological classiﬁcation is accepted. The rules 
of this classiﬁcation have to be learnt but are highly reproducible in all 
published series. This classiﬁcation will help to elaborate therapeutic 
protocols for prospective clinical studies. The variability of clinical 
presentation and behaviour still requires several clinicopathologic 
correlations. Modern techniques of immunostochemistry, molecular 
techniques and gene expression will improve the diagnosis and open 
new horizons for an indiviualized therapy. 
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Thymic epithelial tumors (TET) are uncommon, with a broad spectrum 
of biologic and morphologic features. Of several proposed classiﬁca-
tions, WHO histologic classiﬁcation reﬂects both the clinical and the 
functional features of TET and thus contributes to the clinical assess-
ment and treatment of patients with these tumors (1, 2). Recently, sev-
eral reports described speciﬁc CT, MR imaging, and FDG-PET features 
of TET that reﬂect the WHO histologic subtypes (3-7). In this section, 
we discuss imaging features of TET correlated with histologic subtypes.
Computed Tomography (CT)
Because of embryologic background and anatomic location, TET can 
occur adjacent to the junction of the great vessels and the pericardium; 
less commonly, in the cardiophrenic angles or adjacent cardiac borders; 
and, rarely in the neck or other mediastinal compartments (8). CT has a 
much higher sensitivity for detecting TET than conventional radiog-
raphy, and also allows evaluation of (a) invasion of the surrounding 
mediastinal fat, vascular structures, and adjacent lung; and (b) the pres-
ence of pleural and extrapleural seeding. On CT scans, TET usually ap-
pear as homogeneous, oval, rounded or lobulated soft-tissue masses in 
the anterior mediastinum (8). In cases of invasive thymoma or thymic 
carcinoma, invasion of the mediastinal fat or adjacent structures as well 
as pleural seeding may be seen.
Tomiyama et al (3) assessed the CT features of various subtypes of 
TET and reported that smooth contours and a round shape are most 
suggestive of type A tumors, irregular contours are most suggestive of 
type C tumors, and calciﬁcation is suggestive of type B tumors. Jeong 
et al (5) reviewed the CT ﬁndings correlated with simpliﬁed WHO 
classiﬁcation of TET (low-risk thymomas (type A, AB, and B1); high-
risk thymomas (type B2 and B3); thymic carcinomas (type C)) and 
prognosis. CT ﬁndings that are more common in high-risk thymomas 
and thymic carcinomas include lobulated contour, mediastinal fat inva-
sion, and great vessel invasion. Findings associated with signiﬁcantly 
more frequent recurrence and metastasis include lobulated or irregular 
contour, oval shape, mediastinal fat invasion or great vessel invasion, 
and pleural seeding. 
Copyright © 2007 by the International Association for the Study of Lung Cancer S261
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
MR Imaging
At MR imaging, types A, AB, and B1 thymomas have similar or 
slightly higher signal intensity (SI) than that of muscle on T1-weighted 
images (T1WI) and higher SI than that of muscle on T2-weighted 
images (T2WI) (4, 6, 9-12). At Gd-DTPA enhanced MR imaging, 
homogeneous and moderate enhancement is observed. Most B2 and B3 
thymomas manifest inhomogeneous SI with scattered high-intensity ar-
eas on T2WI, which are corresponded to cystic spaces with or without 
hemorrhage on pathologic examination (6). In a study by Sakai et al 
(6), T2WI indicated that six of 12 invasive thymomas (probably WHO 
type B2 or B3) had lobular internal architecture, with 1- to 2-mm-thick 
low SI lines; for the ﬁve benign thymomas (probably WHO type A, 
AB, B1), this was not, however, the case. Unlike types A, AB, B1, B2, 
and B3 tumors, thymic carcinomas show relatively low SI at both T1- 
and T2WI, appearing as slightly inhomogeneous lesions (12).
FDG- PET
In TET, FDG-PET may be useful in differentiating thymic carcinoma 
from other thymic tumors, thymic hyperplasia, and normal physiologic 
uptake (13). Sasaki et al (7) reported that the standardized uptake value 
(SUV) for thymic carcinoma was signiﬁcantly greater than that for 
invasive or non-invasive thymoma. With an SUV cutoff point of 5.0, 
thymic carcinoma can be differentiated from thymoma with reasonably 
high sensitivity (84.6%), speciﬁcity (92.3%), and accuracy (88.5%). 
There was no statistically signiﬁcant difference in SUV between inva-
sive and non-invasive thymomas.
Conclusions
An awareness of the various imaging ﬁndings of the different types of 
TET, as reﬂected in the WHO histologic classiﬁcation, may be helpful in 
clinical practice for the assessment and treatment of patients with TET.
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Background: Thymoma, thymic carcinoma, and thymic carcinoid 
are derived from the epithelium of the thymus, and are described as 
Thymic epithelial tumors. These neoplasms are well-known for het-
erogeneity in the oncological behaviors, variability in the histological 
appearance, and association with autoimmune diseases represented by 
myasthenia gravis. The main strategy of treatment for thymic epithelial 
tumors is supposed to be surgical resection. There have been many 
reports studying prognostic factors including Masaoka staging system, 
completeness of resection, size of the tumor, the involved organs, and 
association with myasthenia gravis. On the other hand, pathological 
classiﬁcation of thymic epithelial tumors has been confusing and the 
clinical signiﬁcance of histological appearance has been unclear. World 
Health Organization (WHO), however, established a consensus on the 
histological classiﬁcation of the thymic epithelial tumors in 1999.
Aim: We aimed to elucidate the prognostic factors responsible for 
survival, and examined the outcome of surgical treatment based on 272 
patients between 1957 and 2001.
Results: The number of patients according to Masaoka stage is 113 in 
stage I, 64 in stage II, 71 in stage III, 11 in stage IVa, and 13 in stage 
IVb. The number of patients according to World Health Classiﬁcation 
system is 17 in type A, 65 in type AB, 50 in type B1, 89 in type B2, 23 
in type B3 and 28 in type C. 
The proportion of invasive tumor was 11%, 42%, 47%, 69%, 85%, 
and 94%, in type A, AB, B1, B2, B3, and C tumor, respectively. The 
proportion of tumors with involvement of the great vessels was 0%, 
4%, 7%, 17%, 19% and 43% in type A, AB, B1, B2, B3, and C tumor, 
respectively. The proportion of association with myasthenia gravis was 
0%, 7%, 40%, 56%, 10%, and 0% in type A, AB, B1, B2, B3, and C 
tumor, respectively.
According to Masaoka staging system, 10-year survival rate was 99%, 
95%, 91%, 36% and 0% in stage I, II, III, IVa and IVb disease, respec-
tively. According to WHO histological classiﬁcation system, 10-year 
survival rate was 100%, 96%, 97%, 92%, 78% and 68% in type A, AB, 
B1, B2, B3, and C tumor, respectively.
Multivariate analysis was done to determine the independent prognos-
tic factor in thymomas. Masaoka staging system and WHO histologic 
classiﬁcation were the signiﬁcant factors while age, gender, association 
with myasthenia gravis, completeness of resection or involvement of 
the great vessels were not.
Conclusion: Stage and histology are signiﬁcant prognostic factors and 
should be considered when determining the strategy for treatment.
E13-04 Insights into Thymic Epithelial Tumor, Tue, Sept 4, 16:00 – 17:30
Radiation therapy for thymic epithelial neoplasms
Thomas, Charles R. 
Oregon Health & Science University, Portland, OR, USA
Pre-operative Radiation Therapy
For locally advanced, large, invasive thymomas that are unresectable or 
marginally resectable, preoperative adjuvant radiation therapy has been 
advocated to render it resectable. Several studies on limited numbers of 
